Spotlight Innovation Inc. of West Des Moines announced it has obtained exclusive worldwide rights from the Florida State University Research Foundation to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus infection. Included among the licensed compounds are those identified in a study co-authored by Florida State University Professor Hengli Tang that was published in Nature Medicine in August. Tang and his research team collaborate with Spotlight Innovation as part of an existing sponsored research agreement. He is also a member of the company’s scientific advisory board. Spotlight Innovation specializes in advancing technologies to address rare, emerging and neglected diseases.